CN-122005783-A - Application of humanized DKK-1 monoclonal antibody in preparation of immunity-enhancing drugs

Abstract

The invention discloses an application of a humanized DKK-1 monoclonal antibody in preparation of a medicament for enhancing immunity, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2. Animal experiments prove that the humanized DKK-1 monoclonal antibody can effectively improve the CD8 + T cell proportion in peripheral blood of an aging mouse and reduce the inflammatory factor level in serum, and provides a new treatment scheme for enhancing immunity.

Inventors

• SONG CHUNLI
• Yuan Wanqiong
• XIA WEIBO
• LI MEI
• ZHANG DAPENG
• QIAN WEIZHU
• HOU SHENG

Assignees

• 北京大学第三医院（北京大学第三临床医学院）

Dates

Publication Date

20260512

Application Date

20260320

Claims (8)

1. 1. The application of the humanized DKK-1 monoclonal antibody in preparing the immunity enhancing medicine is disclosed, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2.
2. 2. The use according to claim 1, which is for elderly people.
3. 3. The use of claim 1, further comprising ameliorating inflammation.
4. 4. The use of claim 1, comprising increasing the proportion of CD8 + T cells in peripheral blood while reducing the level of inflammatory factors in serum.
5. 5. The use of claim 4, wherein the inflammatory factor comprises IFN-gamma, IFN-beta, and IL-27.
6. 6. The use according to claim 1, wherein the medicament is an injection.
7. 7. The use according to claim 6, wherein the medicament is a subcutaneous injection.
8. 8. The use according to claim 6, wherein the medicament further comprises other pharmaceutical excipients or the medicament is a freeze-dried powder injection.

Description

Application of humanized DKK-1 monoclonal antibody in preparation of immunity-enhancing drugs Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of a humanized DKK-1 monoclonal antibody in preparation of a medicine for enhancing immunity. Background Immunity is not only the resistance of human body to diseases, but also a protective function of the organism. It is well known that the main line of defense of the human body consists of hundreds of millions of immune cells, which are responsible for preventing invasion of pathogenic microorganisms (bacteria, viruses, etc.), identifying and eliminating aged and dead cells, monitoring the task of possibly occurring chromosomal aberrations or genetically mutated cells, and once these abnormalities are found, timely elimination of the lesions is possible. The body with low immunity is easy to be infected or suffering from cancer, in this case, bacteria, viruses, fungi and the like are easy to be infected, so the most direct manifestation of low immunity is easy to be ill. Because of frequent illness and aggravated consumption of organisms, the health and weakness, malnutrition, listlessness, fatigue and weakness, appetite reduction, sleep disturbance and other manifestations are common, and the medical injection and medication are convenient for family use. Each illness takes a long time to recover and often recurs. The medicine is used for improving immunity, is inconvenient, and often brings a series of side reactions, thus causing pains to the daily life of patients. The reported DKK-1 antibodies mainly comprise DKN-01, BHQ-880, DKK1-A2, RH2-18 and Hetero-DS. Wherein DKN-01 is human anti-DKK-1 IgG4 monoclonal antibody developed by LeapTherapeutics, and is used for treating various tumors, such as cholangiocarcinoma, intimal carcinoma, gastric cancer, esophageal cancer, liver cancer, ovarian cancer and prostatic cancer, and is in clinical stage II. BHQ-880 can be used for the treatment of multiple myeloma and osteosarcoma. DKK1-A2 recognizes DKK 1P 20 peptide fragments for use in the treatment of blood and solid cancer cells. RH2-18 can be used for treating postmenopausal osteoporosis. The Hetero-DS can treat postmenopausal osteoporosis and bone fractures. In the prior Chinese patent No. CN119318703B of the inventor, the application of the humanized DKK-1 monoclonal antibody in preparing a medicament for treating Alzheimer's disease is disclosed, and animal experiments prove that the humanized DKK-1 monoclonal antibody can prolong the survival time of mice with Alzheimer's disease, improve the cognitive level of the mice with Alzheimer's disease, improve the memory capacity of the mice with Alzheimer's disease and reduce blood sugar, and the humanized DKK-1 monoclonal antibody has the effect of treating Alzheimer's disease and can relieve senile dementia. From the above, the DKK-1 antibody is mainly focused on treating fracture, osteoporosis, cancer and Alzheimer's disease, and the related researches on enhancing immunity and the like are rarely reported. Further researches show that the humanized DKK-1 monoclonal antibody has a certain effect on enhancing immunity, and the application is further completed. Disclosure of Invention In order to solve the problems, the invention provides an application of a humanized DKK-1 monoclonal antibody in preparing a medicament for enhancing immunity, and specifically provides the following technical scheme: The invention provides an application of a humanized DKK-1 monoclonal antibody in preparation of a medicament for enhancing immunity, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2. In a preferred embodiment of the invention, the application is directed to elderly people. In a preferred embodiment of the invention, the use further comprises ameliorating inflammation. In a preferred embodiment of the invention, this includes increasing the proportion of CD8 + T cells in peripheral blood while reducing the level of inflammatory factors in serum. In a preferred embodiment of the invention, the inflammatory factors include IFN-gamma, IFN-beta and IL-27. In a preferred embodiment of the invention, the medicament is an injection. In a preferred embodiment of the invention, the medicament is an injection for subcutaneous injection. In a preferred embodiment of the present invention, the medicament further comprises other pharmaceutical excipients or the medicament is a freeze-dried powder injection. The humanized DKK-1 monoclonal antibody provided by the invention has the beneficial effects that animal experiments prove that the humanized DKK-1 monoclonal antibody can effectively improve the CD8 + T cell proportion in peripheral blood of an aging mouse and reduce the inflammatory factor level in serum, and a novel treatment scheme is provided for enhancing immunity. Drawings FIG. 1 is a statistic